In November 2015, Uniseed started its third and largest fund (Fund-3), with the five partners each committing $10 million over 10 years (total fund $50 million). This followed three high profile exits in the preceding 14 months (Fibrotech sale to Shire; Spinifex sale to Novartis & Hatchtech sale to Dr Reddys Laboratories).
In March 2017, Uniseed announced the further commitment to a $20 million Follow-on Fund.
In January 2018 a Co-Investment Fund was established with private capital providers through a relationship with Stoic Venture Capital, a division of Atlas Advisors Australia.
In March 2022, Uniseed announced strategic partnership and a further commitment of $75 Million from UniSuper.
Hear what Researchers and CEO’s of Uniseed startups say about working with Uniseed.